Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extracorporeal shockwave therapy after botulinum toxin for cuff muscle spasticity in multiple sclerosis
IRCT20200825048515N41Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of neuronox in multiple sclerosis (MS) and Muscle spasm (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Improvement in cuff muscle spasticity. Started Sep 2021; status: completed.
02
Drugs
neuronox
03
Conditions
multiple sclerosis (MS)Muscle spasm
Beyond the preview
Go deeper on IRCT20200825048515N41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200825048515N41.